# Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).

> **NCT00792623** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 45 (actual)

## Conditions studied

- Varicella

## Interventions

- **BIOLOGICAL:** VarilrixTM

## Key facts

- **NCT ID:** NCT00792623
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09-08
- **Primary completion:** 2007-09-10
- **Final completion:** 2007-09-10
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2018-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00792623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00792623, "Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00792623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*